Insulin-like growth factor-I and cancer mortality in older men
- PMID: 20080855
- PMCID: PMC2841529
- DOI: 10.1210/jc.2009-1378
Insulin-like growth factor-I and cancer mortality in older men
Abstract
Context: Although numerous studies have explored the relation of IGF-I with cancer incidence, few have investigated the association between IGF-I and cancer mortality.
Objective: This study examined the association of serum IGF-I levels with cancer mortality in older community-dwelling men.
Design, setting, and participants: We conducted a prospective, population-based study of 633 men aged 50 yr and older (mean = 73) who attended a 1988-1991 research clinic visit when blood was obtained for measurement of IGF-I. Participants were followed for vital status through July 2006.
Main outcome measure: All-cancer mortality was assessed.
Results: Median IGF-I was 96 ng/ml. During the 18-yr follow-up, 368 deaths occurred; 74 (20%) were due to cancer. Cox regression analyses showed a significant quadratic association between IGF-I and all-cancer mortality (P = 0.039). Higher levels of IGF-I were associated with progressively higher risk of cancer death after adjusting for age, IGF-binding protein-1, adiposity, exercise, current smoking, and previous cancer. The adjusted risk of cancer death was statistically significant for IGF-I levels above 120 ng/ml, with magnitudes of effect ranging from 1.61 [95% confidence interval (CI) = 1.28-2.02] to 2.61 (95% CI = 1.46-4.64). For the 46% of men with IGF-I above 100 ng/ml, the risk of fatal cancer was 1.82 (95% CI = 1.11-2.96) compared to the risk with lower levels.
Conclusions: Higher serum IGF-I in older men is associated with increased risk of cancer death, independent of age, adiposity, lifestyle, and cancer history. These results suggest caution in the use of IGF-I-enhancing therapies to slow the adverse effects of aging.
Figures
Similar articles
-
The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study.J Clin Endocrinol Metab. 2010 Oct;95(10):4616-24. doi: 10.1210/jc.2010-0940. Epub 2010 Jul 7. J Clin Endocrinol Metab. 2010. PMID: 20610588
-
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7. doi: 10.1093/jnci/92.23.1910. J Natl Cancer Inst. 2000. PMID: 11106682
-
Both low and high serum IGF-I levels associate with cancer mortality in older men.J Clin Endocrinol Metab. 2012 Dec;97(12):4623-30. doi: 10.1210/jc.2012-2329. Epub 2012 Sep 26. J Clin Endocrinol Metab. 2012. PMID: 23015658
-
Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke.J Clin Endocrinol Metab. 2007 Apr;92(4):1319-25. doi: 10.1210/jc.2006-1631. Epub 2007 Jan 30. J Clin Endocrinol Metab. 2007. PMID: 17264182
-
The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study.J Clin Endocrinol Metab. 2004 Jan;89(1):114-20. doi: 10.1210/jc.2003-030967. J Clin Endocrinol Metab. 2004. PMID: 14715837
Cited by
-
Comparative endocrinology of aging and longevity regulation.Front Endocrinol (Lausanne). 2011 Nov 23;2:75. doi: 10.3389/fendo.2011.00075. eCollection 2011. Front Endocrinol (Lausanne). 2011. PMID: 22654825 Free PMC article.
-
Growth hormone, insulin and aging: the benefits of endocrine defects.Exp Gerontol. 2011 Feb-Mar;46(2-3):108-11. doi: 10.1016/j.exger.2010.08.020. Epub 2010 Sep 17. Exp Gerontol. 2011. PMID: 20851173 Free PMC article. Review.
-
The proliferating role of insulin and insulin-like growth factors in cancer.Trends Endocrinol Metab. 2010 Oct;21(10):610-8. doi: 10.1016/j.tem.2010.06.007. Epub 2010 Jul 19. Trends Endocrinol Metab. 2010. PMID: 20663687 Free PMC article. Review.
-
Physical activity in relation to circulating hormone concentrations in 117,100 men in UK Biobank.Cancer Causes Control. 2021 Nov;32(11):1197-1212. doi: 10.1007/s10552-021-01466-6. Epub 2021 Jul 3. Cancer Causes Control. 2021. PMID: 34216337 Free PMC article.
-
Targeting the insulin-like growth factor-1 receptor in human cancer.Front Pharmacol. 2013 Mar 22;4:30. doi: 10.3389/fphar.2013.00030. eCollection 2013. Front Pharmacol. 2013. PMID: 23525758 Free PMC article.
References
-
- American Cancer Society 2007 Cancer Facts and Figures. Atlanta: American Cancer Society
-
- Moschos SJ, Mantzoros CS 2002 The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63:317–332 - PubMed
-
- Pollak M 2000 Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224–1228 - PubMed
-
- Djavan B, Waldert M, Seitz C, Marberger M 2001 Insulin-like growth factors and prostate cancer. World J Urol 19:225–233 - PubMed
-
- Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC 1997 Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57:4667–4672 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials